Magna update: settlement under review, deadline on jpyo

New Post Public Reply Private Reply Replies (0) Message Board
freegriff
510
Magna update: settlement under review, deadline on jpyo extended to Nov 17

"October 26, 2023
By ECF
Hon. Loretta A. Preska
United States District Judge
Southern District of New York
500 Pearl Street
New York, NY 10007
Re: SEC v. Joshua Sason, et al., 19 Civ. 1459 (LAP)
Dear Judge Preska:
Plaintiff Securities and Exchange Commission (the “SEC” or “Commission”) and
Defendants Joshua Sason, Marc Manuel, and Magna Management, LLC, Magna Equities II, LLC,
and MG Partners, Ltd. (collectively, the “Magna Entities”) respectfully request that the Court
adjourn the deadline for the submission of a joint pretrial order (“JPTO”) for two reasons.1
First, counsel for the SEC and for Defendants Sason and the Magna Entities have continued
to participate in a mediation process with Magistrate Judge Aaron. On October 25, 2023, Judge
Aaron provided the parties with a settlement proposal and requested that the parties respond by
October 30, 2023. The parties are currently considering Judge Aaron’s proposal.
Second, as the Court is aware, SEC counsel reached a settlement in principle with Defendant
Manuel and agreed to recommend settlement terms to the five-member Commission that, if
authorized, would resolve the SEC’s claims against Manuel. Before SEC counsel can make that
recommendation, Manuel must sign a consent to a proposed final judgment, certain language in
which counsel for the SEC and Manuel have been negotiating. The Court previously set a date of
November 17, 2023, for the SEC and Manuel to provide the Court with a status update regarding
the Commission’s consideration of the settlement. (Dkt. 202.)
Accordingly, because the parties expect there to be more clarity soon regarding the claims, if
any, to be tried, the parties respectfully request that the Court adjourn the November 7, 2023, JPTO
deadline sine die, and set a new deadline after receiving the parties’ November 17, 2023, status report.
This is the parties’ third request for an adjournment of the JPTO deadline. The Court
previously granted the parties’ requests to extend the JPTO deadline from October 10, 2023, to
October 24, 2023 (Dkt. 200), and from October 24, 2023, to November 7, 2023. (Dkt. 205.)
Respectfully submitted,
/s/
Daniel Loss / David Zetlin-Jones / Eric Taffet
Counsel to the SEC
cc: All counsel of record by ECF
1
The JPTO deadline does not affect Defendants Kautilya Sharma, Perian Salviola, and Pallas
Holdings, LLC, for whom all issues of liability were resolved on summary judgment."

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

York Space Systems Faces Class Action Over Misleading IPO

Updated Category News Views 2

York Space Systems Under the Legal Spotlight Ever get that feeling when something just doesn’t sit right? Like a burr under the saddle, York Space Systems is now grappling with a class action lawsuit that's throwing a heap of shade on its recent moves. What’s at play? Bronstein, Gewirtz & Grossman, LLC, a law firm that seems to have a nose for corporate messes, has...

Continue Reading
Hims & Hers Faces Class Action: Investors Beware

Updated Category News Views 1

Allegations and Legal Pressure There's trouble brewing in the land of health and wellness apps, with Hims & Hers Health, Inc. (NYSE:HIMS) taking center stage. Slap on your glasses, folks, because this one's a doozy. A class-action lawsuit has exploded against the company and some of its officers—allegations flying as they focus on serious accusations of misleading...

Continue Reading
ATTACK SHARK Partners with Cloud9 League Team

Updated Category News Views 2

Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...

Continue Reading
FDI Launches 'Generation Smile' for Global Oral Health

Updated Category News Views 2

A New Kind of Movement Imagine a campaign not bound by age or geography but united by a shared mission. Generation Smile, freshly launched by the FDI World Dental Federation in Prague, is just that kind of uprising. This initiative redefines existing approaches to oral health, pushing beyond the boundaries of mere dental care to emphasize the integral role oral health...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 3

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading
Pudu D7 Robot Shines at IFA, Setting New Robotics Bar

Updated Category News Views 2

Breaking New Ground in Robotics at IFA Well, here's a nugget for robotics buffs and investors alike: Pudu Robotics, a heavyweight in commercial service robotics, is carving out a fresh chapter with its PUDU D7. Making waves as an honoree at the IFA Innovation Awards, the D7 presents a mash-up of brains and brawn—exemplifying the future path for robotics. The PUDU D7...

Continue Reading
EyePoint Stumbles: Legal Eagles Circle Post-Trial Flop

Updated Category News Views 1

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

Continue Reading
Morpho Unveils Versatile UV Printer at IFA 2026

Updated Category News Views 4

IFA 2026: A New Frontier for Desktop Printing You've seen your fair share of printers over the years, but when a company like Morpho steps onto the scene with a gadget that echoes innovation, it makes you perk up those market-ears. We're talking the big unveil of their desktop UV printer at the IFA 2026 in Berlin. Morpho's contraption isn't just spewing out ink; it's...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 4

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
Midea's VitaBreeze: Revolutionizing Personalized Climate

Updated Category News Views 2

A Fresh Breeze in Climate Control Here's something that'll shake up your household. Midea just announced their latest gizmo, called VitaBreeze, and they’re not messing around. They introduced it at IFA 2026, promising it's not just for cooling off in the summer or heating in the winter. Oh no, my friends, they've packed this unit with enough cutting-edge tech that...

Continue Reading

Top 5 Most Recently Viewed Articles

Hoyne Bancorp's Transition to Stock Holding Company Explained

Updated Category News Views 240

Hoyne Bancorp, Inc. Announces Conversion Approval Hoyne Bancorp, Inc., a leading financial institution, has recently completed a significant milestone in its evolution. This marks an important phase as the organization transitions from a mutual holding company to a stock holding company, a move that is poised to enhance its operational framework. By transforming into a...

Continue Reading
Incyte's INCB123667 Demonstrates Promise for Ovarian Cancer

Updated Category News Views 133

Incyte's Advancements with INCB123667 Incyte, a forward-thinking biopharmaceutical company known for its innovative therapies, has revealed promising early-stage clinical results for its CDK2 inhibitor, INCB123667. This potential game-changer is designed to target advanced solid tumors, particularly ovarian cancer, where there are still significant unmet medical needs....

Continue Reading
GCL SI Highlights Innovations and Solutions for Solar Energy

Updated Category News Views 167

GCL SI Showcases Innovations at Intersolar Europe At Intersolar Europe 2025, GCL System Integration (GCL SI) presents groundbreaking technologies and comprehensive solar solutions, demonstrating its significant role in photovoltaic advancement. From cutting-edge granular silicon to high-efficiency perovskite modules, GCL is at the forefront of global decarbonization...

Continue Reading
8x8, Inc. Celebrates Inclusion in Newsweek's Excellence Ranking

Updated Category News Views 177

8x8, Inc. Recognized by Newsweek for Corporate Excellence 8x8, Inc. (NASDAQ: EGHT) has recently been acknowledged in the prestigious Excellence 1000 Index published by Newsweek. This esteemed ranking celebrates companies demonstrating outstanding practices in various crucial areas such as financial responsibility and social accountability. Understanding the Excellence...

Continue Reading
James Hardie Industries Faces Leadership Change Amid Lawsuit

Updated Category News Views 183

James Hardie Industries Faces Leadership Turmoil Recently, James Hardie Industries plc (NYSE: JHX) announced a significant leadership transition with the departure of its Chief Financial Officer, Rachel Wilson. Ryan Lada has been brought in as her replacement. This change comes in the wake of troubling developments concerning the company's financial practices and investor...

Continue Reading